Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice

Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects

(2018) Manabu Kato et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction

(2018) Marianne Lachaux et al.   DIABETES OBESITY & METABOLISM

Hypertension with diabetes mellitus complications

(2018) Daisuke Yamazaki et al.   HYPERTENSION RESEARCH

The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure

(2018) Hui Pei et al.   MEDICINE

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney DiseaseNovelty and Significance

(2017) Lionel Lattenist et al.   HYPERTENSION

Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?

(2017) Ali Nehme et al.   HYPERTENSION RESEARCH

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy

(2017) Shigehiro Katayama et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Modelling diabetic nephropathy in mice

(2017) Kengo Azushima et al.   Nature Reviews Nephrology

Beneficial and harmful effects of exercise in hypertensive patients: the role of oxidative stress

(2016) Milica Dekleva et al.   HYPERTENSION RESEARCH

Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension

(2016) Shigeru Shibata et al.   HYPERTENSION RESEARCH

Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys

(2016) Makiko Yamada et al.   XENOBIOTICA

Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial

(2015) Sawako Kato et al.   Clinical and Experimental Nephrology

Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis

(2015) Jing Hou et al.   CLINICAL THERAPEUTICS

Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Potassium Handling with Dual Renin-Angiotensin System Inhibition in Diabetic Nephropathy

(2014) P. N. Van Buren et al.   Clinical Journal of the American Society of Nephrology

Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury

(2014) Peter Kolkhof et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease

(2014) L. L. Huang et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial

(2014) Katsuyuki Ando et al.   Lancet Diabetes & Endocrinology

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: An emerging paradigm in diabetic nephropathy

(2013) Thomas A. Mavrakanas et al.   European Journal of Internal Medicine

Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT1 Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice

(2013) Kazi Rafiq et al.   PLoS One

Renal Sympathetic Denervation Suppresses De Novo Podocyte Injury and Albuminuria in Rats With Aortic Regurgitation

(2012) Kazi Rafiq et al.   CIRCULATION

Mineralocorticoid receptor–Rac1 activation and oxidative stress play major roles in salt-induced hypertension and kidney injury in prepubertal rats

(2012) Hiroo Kawarazaki et al.   JOURNAL OF HYPERTENSION

Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan

(2012) Bai Lei et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Oxidative Stress-Induced Glomerular Mineralocorticoid Receptor Activation Limits the Benefit of Salt Reduction in Dahl Salt-Sensitive Rats

(2012) Kento Kitada et al.   PLoS One

Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor–dependent pathway

(2011) Shigeru Shibata et al.   JOURNAL OF CLINICAL INVESTIGATION

New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Mineralocorticoid-Receptor Blockers Exert Antihypertensive and Renoprotective Effects Independently of the Renin–Angiotensin System

(2010) Akira Nishiyama et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Pharmacological Effects of Mineralocorticoid-Receptor Blockers

(2009) Akira Nishiyama et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Mouse Models of Diabetic Nephropathy

(2009) F. C. Brosius et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease

(2008) Shigeru Shibata et al.   NATURE MEDICINE